Back to News
Market Impact: 0.15
Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
Source: globenewswire.com
Healthcare & BiotechProduct Launches
Two oral presentations will feature the first combination data for ziftomenib: with quizartinib in newly diagnosed AML and with gilteritinib in relapsed/refractory NPM1/FLT3 co-mutated AML. The announcement provides no study results or efficacy figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- SpaceX signs deal with Qualcomm to provide network technology for U.S. mobile service
- CVS Plans to Break Up $117 Billion Healthcare Conglomerate
- How Abdul El-Sayed would build Medicare for All, from a wealth tax to a Fed-style governing board
- BillionToOne SVP John ten Bosch sells $320,723 in stock
- Novo raises full-year outlook as Wegovy sales impress
- Sight Sciences earnings missed by $0.48, revenue topped estimates